Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

COMETRIQ for Medullary thyroid cancer: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 10 adverse event reports in the FDA FAERS database where COMETRIQ was used for Medullary thyroid cancer.

Most Reported Side Effects for COMETRIQ

Side Effect Reports % Deaths Hosp.
Off label use 75 49.7% 19 11
Fatigue 48 31.8% 8 9
Diarrhoea 39 25.8% 10 7
Stomatitis 29 19.2% 2 6
Nausea 23 15.2% 2 6
Death 20 13.3% 20 7
Decreased appetite 18 11.9% 6 4
Dry mouth 16 10.6% 0 1
Malignant neoplasm progression 16 10.6% 13 3
Pain in extremity 16 10.6% 1 1
Dysgeusia 15 9.9% 0 2
Dysphonia 15 9.9% 3 2
Asthenia 14 9.3% 3 7
Dyspnoea 13 8.6% 4 3
Hair colour changes 10 6.6% 0 1

Other Indications for COMETRIQ

Thyroid cancer (64) Prostate cancer (28) Renal cancer (18) Lung neoplasm malignant (7)

Other Drugs Used for Medullary thyroid cancer

VANDETANIB (221) CABOZANTINIB S-MALATE (165) SELPERCATINIB (116) CABOZANTINIB (73) PRALSETINIB (48) LENVATINIB (34) SORAFENIB (18) CAPRELSA (14) OCTREOTIDE (14) TARLATAMAB-DLLE (13)

Related Pages

COMETRIQ Full Profile All Medullary thyroid cancer Drugs COMETRIQ Demographics COMETRIQ Timeline